Twelve months later, Miller is healthy and preparing to host her family's holiday gathering. A regimen of biological drugs ...

1. Brenner A, Youssef M, Kumthekar P, et al. Rhenium (¹⁸⁶Re) obisbemeda (rhenium nanoliposome, ¹⁸⁶RNL) for the treatment of ...

PLT012, a groundbreaking anti-CD36 antibody, enters clinical trials to enhance immune responses in solid tumors, promising ...

The FDA's fast track designation acknowledges the combination's promising early efficacy and safety profile in treating MSS mCRC. Early data from a phase 1b/2 study showed deep, durable responses with ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to muzastotug when used in combination with Keytruda (pembrolizumab) to treat adult patients with microsatellite stable ...

At certain point of cancer progression, primary localized tumors may disseminate to distant organs, including lymph nodes, lungs, bones, liver, or brain. The current options to treat cancer metastases ...

Scientists have identified a promising strategy to improve liver cancer immunotherapy: targeting B-cells. While immunotherapy ...

Recurrent or metastatic nasopharyngeal carcinoma is an aggressive disease, and long-term survival with chemotherapy alone is ...

The trial results support Tukysa-Herceptin-Perjeta as yet another option for breast cancer patients in the frontline ...

SABCS 2025 analysis shows persistent racial and socioeconomic gaps in metastatic HR+/HER2 negative breast cancer diagnosis ...

My best advice for anyone recently diagnosed with MBC is to keep a notebook and take someone with you to every appointment.

While new late-stage data point to some liver toxicity signals, analysts at BMO Capital Markets said Tukysa’s efficacy ...